Dalfampridine ( DrugBank: Dalfampridine )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
4	Primary lateral sclerosis	1
13	Multiple sclerosis/Neuromyelitis optica	10

4. Primary lateral sclerosis

---

Clinical trials : 5 /  Drugs : 13 - (DrugBank : 6) / Drug target genes : 13 - Drug target pathways : 25

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02868567 (ClinicalTrials.gov)	March 2016	17/3/2016	Use of Dalfampridine in Primary Lateral Sclerosis	A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis	Motor Neuron Disease, Upper	Drug: dalfampridine	Hospital for Special Surgery, New York	NULL	Active, not recruiting	18 Years	99 Years	All	35	Phase 1	United States

13. Multiple sclerosis/Neuromyelitis optica

---

Clinical trials : 3,340 /  Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05730738 (ClinicalTrials.gov)	June 1, 2021	5/12/2021	Dalfampridine in Egyptian Patients With Multiple Sclerosis	Effect of Dalfampridine on Gait Impairment, Cognition and Fatigue in Egyptian Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Dalfampridine ER, 10 Mg Oral Tablet, Extended Release;Drug: Placebo	Ain Shams University	NULL	Recruiting	18 Years	N/A	All	100	N/A	Egypt
2	EUCTR2014-003498-41-AT (EUCTR)	22/09/2015	06/08/2015	Effects of dalfampridine on mobility in the context of daily life	Effects of dalfampridine on mobility in the context of daily life - Fampridine Study in Activities of Daily Living	Motor behaviour and cognition in multiple sclerosis patients;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Fampyra INN or Proposed INN: FAMPRIDINE	Medical University of Vienna	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			Austria
3	NCT02391961 (ClinicalTrials.gov)	April 1, 2015	3/3/2015	Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis	Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis	Multiple Sclerosis;Internuclear Ophthalmoplegia;Fatigue	Drug: Dalfampridine;Drug: Placebo	VA Office of Research and Development	NULL	Completed	18 Years	65 Years	All	23	Phase 2	United States
4	NCT02259361 (ClinicalTrials.gov)	November 2014	1/10/2014	Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS	Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study	Multiple Sclerosis	Drug: Sustained-release oral dalfampridine;Drug: Placebo	Sheba Medical Center	NULL	Not yet recruiting	18 Years	70 Years	Both	30	Phase 4	Israel
5	NCT02166346 (ClinicalTrials.gov)	February 2014	16/6/2014	Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)	Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch)	Transverse Myelitis;Neuromyelitis Optica;Idiopathic Transverse Myelitis;Myelitis NOS	Drug: Dalfampridine;Drug: Placebo	Johns Hopkins University	Acorda Therapeutics	Completed	18 Years	70 Years	All	24	Phase 2	United States
6	NCT02006160 (ClinicalTrials.gov)	December 2011	6/6/2012	Effects of Dalfampridine on Cognition in Multiple Sclerosis	Effects of Dalfampridine on Cognition in Multiple Sclerosis	Multiple Sclerosis	Drug: dalfampridine;Drug: placebo	State University of New York at Buffalo	NULL	Completed	18 Years	60 Years	All	61	Phase 2/Phase 3	United States
7	NCT01444300 (ClinicalTrials.gov)	September 2011	20/9/2011	Dalfampridine for Imbalance in Multiple Sclerosis	Dalfampridine to Improve Imbalance in Multiple Sclerosis: A Pilot Study	Multiple Sclerosis;Fatigue	Drug: Dalfampridine;Drug: Placebo	Oregon Health and Science University	Acorda Therapeutics	Completed	20 Years	59 Years	All	24	Phase 2	United States
8	NCT01337986 (ClinicalTrials.gov)	May 2011	13/4/2011	Ampyra for Optic Neuritis in Multiple Sclerosis	Dalfampridine After Optic Neuritis to Improve Visual Function in Multiple Sclerosis	Multiple Sclerosis;Optic Neuritis	Drug: Dalfampridine/Placebo;Drug: Placebo/Dalfampridine	Washington University School of Medicine	Acorda Therapeutics	Completed	18 Years	55 Years	All	53	Phase 2/Phase 3	United States
9	NCT01328379 (ClinicalTrials.gov)	March 2011	29/3/2011	Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis	Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5 mg and 10 mg Twice Daily) in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Dalfampridine-ER 5mg;Drug: Dalfampridine-ER 10mg;Other: Placebo	Acorda Therapeutics	NULL	Completed	18 Years	70 Years	All	430	Phase 3	United States
10	NCT01356940 (ClinicalTrials.gov)	November 2010	18/5/2011	A Placebo Controlled Trial of Dalfampridine ER for Ambulatory Activity in People With Multiple Sclerosis	A Randomized Controlled Double-blind Cross-over Trial of Dalfampridine ER for Effect on Ambulatory Activity in People With Multiple Sclerosis	Multiple Sclerosis	Drug: dalfampridine ER;Drug: placebo	Brown, Theodore R., M.D., MPH	Acorda Therapeutics	Completed	18 Years	75 Years	All	43	Phase 4	United States

Back to top